Erythrocytes as Drug Carriers in Medicine

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology
Cover of the book Erythrocytes as Drug Carriers in Medicine by , Springer US
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781489900449
Publisher: Springer US Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9781489900449
Publisher: Springer US
Publication: June 29, 2013
Imprint: Springer
Language: English

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

More books from Springer US

Cover of the book Extreme Statistics in Nanoscale Memory Design by
Cover of the book Pediatric Dialysis by
Cover of the book Transport Mechanisms in Membrane Separation Processes by
Cover of the book Physiology of Membrane Disorders by
Cover of the book Biological Aspects of Social Problems by
Cover of the book Languages for Digital Embedded Systems by
Cover of the book Human Development and the Spiritual Life by
Cover of the book The Great American Biotic Interchange by
Cover of the book Cancer, AIDS, and Quality of Life by
Cover of the book Cultures, Communities, Competence, and Change by
Cover of the book Recent Advances in Geriatrics by
Cover of the book Copolymerization by
Cover of the book Cardiovascular Disease in the Elderly by
Cover of the book Conductive Polymers and Plastics by
Cover of the book Dictionary of Food Ingredients by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy